Bristol-Myers Squibb Company (BMY)
- Previous Close
48.93 - Open
49.00 - Bid --
- Ask --
- Day's Range
48.87 - 49.56 - 52 Week Range
47.58 - 70.94 - Volume
7,909,874 - Avg. Volume
15,525,840 - Market Cap (intraday)
99.595B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
12.73 - EPS (TTM)
3.86 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 2.40 (4.88%)
- Ex-Dividend Date Apr 4, 2024
- 1y Target Est
56.00
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com34,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BMY
Performance Overview: BMY
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMY
Valuation Measures
Market Cap
99.59B
Enterprise Value
128.78B
Trailing P/E
12.73
Forward P/E
7.06
PEG Ratio (5yr expected)
2.28
Price/Sales (ttm)
2.27
Price/Book (mrq)
3.38
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
6.65
Financial Highlights
Profitability and Income Statement
Profit Margin
17.83%
Return on Assets (ttm)
5.63%
Return on Equity (ttm)
26.53%
Revenue (ttm)
45.01B
Net Income Avi to Common (ttm)
8.02B
Diluted EPS (ttm)
3.86
Balance Sheet and Cash Flow
Total Cash (mrq)
12.28B
Total Debt/Equity (mrq)
140.82%
Levered Free Cash Flow (ttm)
13.78B
Research Analysis: BMY
Company Insights: BMY
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: BMY
Analyst Report: Bristol-Myers Squibb Co.
Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
RatingPrice TargetTechnical Assessment: Neutral in the Intermediate-Term
Was Thursday's large downside reversal yet another one-day wonder? Strength was seen immediately on Friday, cutting into the weekly losses. The daily chart for the major indices all have a "rolling-over" look, with the Nasdaq and Nasdaq 100 (QQQ) appearing to be ahead of the S&P 500 (SPX) for a break lower. As well, the news from the Middle East seems to be getting worse by the day -- but, so far, the U.S stock market and economy seem to be turning a blind eye to the potential implications. Crude oil prices, both WTI and Brent, aren't exploding, but have seen pretty good rallies. WTI hit $87.60/barrel at the end of last week from the low $70s just two months ago, while Brent almost reached $92 last week from $77 in early February.
Market Digest: BMY
Monday Tee Up: Here Come the Big Banks
Large Cap US Pick List - April 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.